Cerus Co. (NASDAQ:CERS) CEO William Mariner Greenman sold 108,011 shares of the stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $3.59, for a total transaction of $387,759.49. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Shares of CERS opened at $4.36 on Friday. The firm has a market capitalization of $624.34 million, a PE ratio of -8.38 and a beta of 1.19. The company’s 50-day moving average is $4.64 and its 200-day moving average is $4.50. Cerus Co. has a fifty-two week low of $2.71 and a fifty-two week high of $6.64. The company has a debt-to-equity ratio of 1.01, a current ratio of 2.55 and a quick ratio of 2.16.
Cerus (NASDAQ:CERS) last issued its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.12) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by ($0.01). Cerus had a negative net margin of 95.44% and a negative return on equity of 112.64%. The company had revenue of $20.92 million during the quarter, compared to the consensus estimate of $20.90 million. Analysts predict that Cerus Co. will post -0.44 earnings per share for the current fiscal year.
Large investors have recently added to or reduced their stakes in the stock. CVA Family Office LLC bought a new position in Cerus during the fourth quarter worth about $42,000. Great West Life Assurance Co. Can bought a new position in Cerus during the fourth quarter worth about $44,000. Exchange Traded Concepts LLC bought a new position in Cerus during the fourth quarter worth about $57,000. Virtu Financial LLC bought a new position in Cerus during the fourth quarter worth about $77,000. Finally, Alpine Global Management LLC bought a new position in Cerus during the fourth quarter worth about $78,000. 69.56% of the stock is currently owned by institutional investors and hedge funds.
Several brokerages have recently weighed in on CERS. ValuEngine raised shares of Cerus from a “hold” rating to a “buy” rating in a research report on Friday, January 3rd. BidaskClub lowered shares of Cerus from a “buy” rating to a “hold” rating in a research report on Saturday, March 14th. BTIG Research began coverage on shares of Cerus in a research report on Wednesday, February 26th. They issued a “buy” rating and a $7.00 price objective on the stock. Finally, Zacks Investment Research raised shares of Cerus from a “sell” rating to a “hold” rating in a research report on Wednesday, March 18th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Cerus has a consensus rating of “Buy” and an average price target of $7.33.
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
See Also: How Buying a Call Option Works
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.